Heart Failure (HF) remains a leading cause of morbidity and mortality worldwide despite major advances in guideline-directed medical therapy. Metabolic remodeling with impaired myocardial energy utilization has emerged as an important therapeutic target in HF. Trimetazidine, a metabolic modulator that partially inhibit...
Akshyaya Pradhan, Sudesh Prajapathi, K. Mahajan et al.· Pharmaceuticals· 0 citations
Low LDL-C target attainment following ACS remains suboptimal despite high-intensity statin therapy, highlighting the need for earlier and more intensive lipid-lowering strategies in high-risk Indian patients.
A. Gautam, Sudesh Prajapathi, Abhishek Singh et al.· American Heart Journal Plus:...· 1 citation
Background/Objectives: Acute coronary syndrome (ACS) and acute decompensated heart failure (ADHF) are associated with substantial short-term morbidity and mortality. The systemic immune–inflammation index (SII) reflects inflammatory and thrombotic activity, but its prognostic value beyond conventional biomarkers and cl...
Y. Khan, Sudesh Prajapathi, Mahadev Meena et al.· Journal of Clinical Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.